Drug Trial Radar · NCT03337698
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
314
Actual
Start
Dec 27, 2017
Primary completion
Oct 14, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor, given in combination as one line of therapy or as two separate lines of therapy, regardless of PD-L1 expression. In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). Participants who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen (Stage 2).
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
AtezolizumabDrug
Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.
CobimetinibDrug
Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.
RO6958688Drug
Cycle 1: RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage. Subsequent cycles: RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle.
DocetaxelDrug
Docetaxel is administered by IV on Day 1 of each 21 day cycle.
CPI-444Drug
CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.
PemetrexedDrug
Pemetrexed is administered by IV on Day 1 of a 21 day cycle.
CarboplatinDrug
Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.
GemcitabineDrug
Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.
LinagliptinDrug
Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.
TocilizumabDrug
Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.
IpatasertibDrug
Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.
BevacizumabDrug
Bevacizumab is administered by IV on Day 1 of each 21-day cycle.
Sacituzumab GovitecanDrug
Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.
RadiationOther
Radiotherapy up to 21 days
EvolocumabDrug
Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.
TiragolumabDrug
Tiragolumab is administered on Day 1 of each 21 day cycle.
XL092Drug
XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.
CamonsertibDrug
Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Percentage of Participants With Objective Response (OR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)Time frame: Up to 50.4 months
Locations
29 sites in 7 countries. Site status is shown where the registry gives one.
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
Las Vegas, Nevada
Columbia University Medical Center
New York, New York
University Hospitals Case Medical Center
Cleveland, Ohio
SCRI Oncology Partners
Nashville, Tennessee
Blacktown Hospital
Blacktown, New South Wales, Australia
Peter Mac Callum Cancer Center
East Melbourne, Victoria, Australia
Centre Georges Francois Leclerc
Dijon, France
Centre Léon Bérard
Lyon, France
Hopital de la Timone
Marseille, France
Institut Régional du Cancer de Montpellier
Montpellier, France
Institut De Cancerologie De L'Ouest
Saint-Herblain, France
Institut Universitaire du Cancer de Toulouse-Oncopole
Toulouse, France
Rambam Medical Center
Haifa, Israel
Rabin Medical Center
Petah Tikva, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)
Songpa-gu, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Fundación Jimenez Díaz
Madrid, Spain
Hospital Universitario HM Sanchinarro-CIOCC
Madrid, Spain
Hospital Regional Universitario de Malaga
Málaga, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Clínica Universidad de Navarra
Pamplona, Navarre, Spain
Barts Cancer Institute
London, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Royal Marsden Hospital
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.